Nordion's constantly evolving business will soon be without proprietary pharma, as the company has agreed to ship out its targeted therapies business for $200 million.
Global CRO Quintiles is planning to slash 400 jobs this year, the company disclosed in a regulatory filing, primarily from its product development and healthcare services departments.
Navidea Biopharmaceuticals has seen its fair share of CMO troubles, as problems with its last contract manufacturer delayed a much-anticipated FDA approval. Now, the diagnostics developer is hitching up with Nordion to manufacture an in-development imaging agent, hoping to avoid more production setbacks.
Perhaps encouraged by the success of its North Carolina neighbor Quintiles, PRA is making moves toward an IPO of its own, filing a confidential draft registration form with the SEC.
BioDuro, PPD's China-based drug discovery business, has opened a state-of-the-art facility in Shanghai, a lab the company says will help it cozy up to clients in the growing Asian biopharmaceutical world.
Amid repeated pipeline struggles and an R&D re-think, Merck KGaA has signed an exclusive deal with the newly public Quintiles, launching a novel collaboration that will give the CRO a seat at the decisionmaking table.
WuXi PharmaTech, China's largest CRO, has big expectations for 2013, and the company is well on its way to following through, posting an 11.7% revenue jump in the first quarter.
Stat Research, a Buenos Aires-based CRO, has reached out to eClinical provider Datatrak in an effort to reduce clinical trial costs and accelerate drug development timelines.
GlaxoSmithKline is turning to market-expansion contractors DKSH to push its antibiotic products in Hong Kong, part of the drugmaker's efforts to cash in on booming Asian demand.
PRA has cut the ribbon on a new facility in Wales, planning to add about 100 new jobs in its informatics unit with help from the local government.
Harlan Laboratories is investing heavily in its Indiana and California facilities, bolstering specialty research by more than doubling its number of isolators.
AMRI's days of posting quarterly net losses appear to be far behind, as the company rode an 11% revenue jump to $6.5 million in net income, up from a negative $3.8 million in the same period last year.
After months of rumor, vagary and anticipation, global CRO Quintiles is finally a public company, raising a total of $947 million after tendering more shares than initially planned.
CRO Simbec Research is using an investment from the Wales Life Sciences Investment Fund to acquire itself from the Canadian Altasciences Group, looking to expand its staff to more than 100 and chase new development deals around the world.
Charles River Labs saw its net profits decline about 2.3% last quarter, as risings costs negated 1.8% revenue growth.
Australia's Novotech has sold off a 30% stake to private equity firm Mercury Capital, planning to use the money to spread its reach across Asia.
Swedish CRO TFS is getting back to M&A, acquiring Beardsworth Consulting Group to bolster its capacity for oncology and vaccine clinical trials.
Covance posted 9.3% revenue growth and a 34.9% jump in profits last quarter, and now the CRO heavyweight is increasing its expectations for the full year.
Parexel International is adding to its business and ticking up its forecast, buying consulting outfit Heron for $24 million and reporting another strong sales quarter.
In a novel deal, U.K. CRO Ergomed has hitched up with Cel-Sci for a Phase III trial of its head and neck cancer drug, but instead of just handling the study, Ergomed is putting up $30 million to fund development in exchange for single-digit royalties from the treatment.